Glucagon-Like Peptide (GLP) Agonist - Pipeline Insight, 2025

This “Glucagon-Like Peptide (GLP) Agonist - Pipeline Insight, 2025” report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in Glucagon-Like Peptide (GLP) Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Glucagon-Like Peptide (GLP) Agonist: Understanding

Glucagon-Like Peptide (GLP) Agonist: Overview

Glucagon-Like Peptide (GLP) agonists are a class of medications primarily used in the treatment of type 2 diabetes mellitus. They mimic the action of endogenous GLP-1, a hormone secreted by the intestine in response to food intake. GLP-1 plays a crucial role in regulating glucose homeostasis by stimulating insulin secretion and inhibiting glucagon release, both of which help to lower blood sugar levels.

Several types of GLP-1 receptor agonists are available, each with unique formulations and dosing regimens. Exenatide, liraglutide, dulaglutide, semaglutide, and lixisenatide are among the most commonly prescribed GLP-1 agonists. These medications are typically administered via subcutaneous injection, with dosing frequency ranging from once-daily to once-weekly injections. Such convenience in dosing improves patient adherence and may contribute to better treatment outcomes.

Glucagon-Like Peptide (GLP) agonists, notably GLP-1 receptor agonists, are pivotal therapeutic targets in type 2 diabetes and obesity management due to their multifaceted effects. They enhance glucose-dependent insulin secretion while inhibiting glucagon release, promoting glycemic control without hypoglycemia. Additionally, GLP-1 agonists curb appetite, foster weight loss, and demonstrate cardiovascular benefits, including reduced major adverse cardiovascular events (MACE). These agents may also preserve pancreatic beta cell function, improve liver health in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), and potentially offer neuroprotective and renoprotective effects. With convenient dosing and potential for combination therapies, GLP-1 agonists stand as promising interventions across various metabolic and neurological conditions, reflecting their substantial clinical significance.

'Glucagon-Like Peptide (GLP) Agonist- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Glucagon-Like Peptide (GLP) Agonist pipeline landscape is provided which includes the disease overview and Glucagon-Like Peptide (GLP) Agonist treatment guidelines. The assessment part of the report embraces, in depth Glucagon-Like Peptide (GLP) Agonist commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glucagon-Like Peptide (GLP) Agonist collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Glucagon-Like Peptide (GLP) Agonist R&D. The therapies under development are focused on novel approaches to treat/improve Glucagon-Like Peptide (GLP) Agonist.

Glucagon-Like Peptide (GLP) Agonist Emerging Drugs Chapters

This segment of the Glucagon-Like Peptide (GLP) Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Glucagon-Like Peptide (GLP) Agonist Emerging Drugs

Survodutide: Boehringer Ingelheim

Survodutide is a glucagon/GLP-1 receptor dual agonist with a novel mechanism of action that activates both the GLP-1 and glucagon receptors that are critical to controlling metabolic functions. Survodutide was co-invented by Boehringer Ingelheim and Zealand Pharma. Survodutide has received US FDA Fast Track Designation as well as a PRIME designation in the EU for the treatment of NASH. Survodutide is being evaluated in Phase III trials for people living with obesity, Non-alcoholic steatohepatitis, and Type 2 diabetes mellitus.

HRS9531: Fujian Shengdi Pharmaceutical

HRS9531 is a dual GLP-1/GIP (glucose-dependent insulinotropic polypeptide) receptor agonist, offering a treatment option for individuals with overweight or obesity, as well as type 2 diabetes. This Phase II study evaluated the efficacy and safety of HRS9531 in obese adults without diabetes. The research found HRS9531 effectively reduced body weight, blood pressure, blood glucose, and triglycerides, with a favorable safety profile. Currently the drug is in Phase III stage of development for the treatment of obesity.

MK-6024: Merck

MK-6024 is an investigational peptide and dual agonist at glucagon-like peptide 1 (GLP-1) and glucagon receptors in clinical development for the treatment of NASH. MK-6024 is being developed under an exclusive licensing agreement between Merck and Hanmi Pharmaceutical for the treatment of patients with NASH. The drug has been granted Fast Track Designation by the US FDA for the treatment of NASH, a more severe form of NAFLD. A Phase IIa clinical trial was conducted that compared the efficacy and safety of efinopegdutide to the GLP-1 receptor agonist semaglutide in patients with NAFLD. The results of this trial were presented at the 2023 European Association for the Study of the Liver (EASL) Annual Congress. Currently, the drug is in Phase II stage of its development for the treatment of Non-alcoholic steatohepatitis.

XW014: Sciwind

XW014 is an orally bioavailable small molecule GLP-1 receptor agonist in development for the treatment of obesity and type 2 diabetes. As a small molecule, XW014 is easier to manufacture than GLP-1 peptide drugs and readily bioavailable after oral dosing. It has the potential to be co-formulated with other oral drugs of complementary mechanisms to generate more effective combination treatments for metabolic diseases. GLP-1 is an incretin peptide hormone that is naturally released after a meal and acts on the digestive tract, liver, pancreas, and central nervous system to maintain physiological health. GLP-1 receptor agonists have shown clinical benefits in treating obesity, type 2 diabetes, and liver disease. Currently, the drug is in Phase I stage of its development for the treatment of Type 2 diabetes mellitus.

Glucagon-Like Peptide (GLP) Agonist: Therapeutic Assessment

This segment of the report provides insights about the different Glucagon-Like Peptide (GLP) Agonist drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Glucagon-Like Peptide (GLP) Agonist

• There are approx. 60+ key companies which are developing the therapies for Glucagon-Like Peptide (GLP) Agonist. The companies which have their Glucagon-Like Peptide (GLP) Agonist drug candidates in the most advanced stage, i.e. Phase III include, Boehringer Ingelheim.

Phases

The report covers around 65+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Glucagon-Like Peptide (GLP) Agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Glucagon-Like Peptide (GLP) Agonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Glucagon-Like Peptide (GLP) Agonist therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glucagon-Like Peptide (GLP) Agonist drugs.

Glucagon-Like Peptide (GLP) Agonist Report Insights

• Glucagon-Like Peptide (GLP) Agonist Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Glucagon-Like Peptide (GLP) Agonist Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Glucagon-Like Peptide (GLP) Agonist drugs?
• How many Glucagon-Like Peptide (GLP) Agonist drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Glucagon-Like Peptide (GLP) Agonist?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Glucagon-Like Peptide (GLP) Agonist therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Glucagon-Like Peptide (GLP) Agonist and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Sciwind
• Boehringer Ingelheim
• Merck
• Eccogene
• Suzhou Alphamab Co., Ltd.

Regor Pharmaceuticals

• Eli Lilly and Company
• Neuraly
• Carmot Therapeutics

Key Products

• XW014
• Survodutide
• MK-6024
• ECC5004
• KN056
• RGT001-075
• Tirzepatide
• CT 388
• Pegylated exenatide

This product will be delivered within 3-5 business days.